Investigation of method for prediction of therapeutic effect of adalimumab initial therapy for inflammatory bowel disease

Investigation of method for prediction of therapeutic effect of adalimumab initial therapy for inflammatory bowel disease - IPADIN study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000022727

Enrollment

Registered

2016-06-14

Start date

2016-04-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative colitis, Crohn&#39

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with IBD who admitted to ofuna chuo hospital for induction therapy of Adalimumab. Patients who gave written informed consent for this study

Exclusion criteria

Exclusion criteria: Patients who are considered not suitable for Adalimumab use due to contraindication or considerable risks such as hypersensitivity to Adalimumab. Other than above mentioned criteria, patients who are judged inappropriate by the doctor.

Design outcomes

Primary

Measure	Time frame
The primary end point was prediction of a clinical response at 6 months.	—

Countries

Japan

Contacts

Public ContactAtsushi Yoshida

Ofuna Chuo Hospital Center for Gastroenterology and Inflammatory Bowel Disease

atushi.y@kza.biglobe.ne.jp+81-46-745-2111

Outcome results